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Summary
Background. Hepatitis C is a curable and preventable disease. People who inject drugs (PWID) and prisoners are at-risk 
groups for acquisition of Hepatitis C Virus (HCV), yet treatment rates remain low. Agonist Opioid Treatment (AOT) and 
needle syringe programs (NSP) reduce HCV transmission, yet coverage, particularly in prisons, is inadequate. ‘Treatment 
as prevention’ is a key public health strategy to help achieve the World Health Organisation (WHO) goal of HCV elimina-
tion by 2030. Aim: To review the recent literature on HCV treatment and prevention in PWID and prisoners. Methods: 
Electronic data base (Medline, PubMed, Cochrane library and Embase) and key website search using search terms related 
to the topic. Results: HCV related disease burden in PWID and prisoners is greater than the general population, yet 
treatment rates remain low. Direct acting anti-virals, mobile elastography, integration of treatment into community and 
prison settings and less restrictive treatment guidelines have removed many treatment barriers.  Treatment adherence and 
outcomes, among PWID (even current injectors) and prisoners are equivalent to the general population. HCV treatment in 
both groups is cost-effective but is dependent on up scaling treatment levels, continuing treatment on prison release and 
preventing re-infection. The public health strategies of treatment as prevention and micro-elimination along with adequate 
coverage of AOT and NSP has the potential to achieve the WHO goal of HCV elimination by 2030. Conclusion: Up-
scaling HCV treatment levels and increasing AOT and NSP coverage among PWID and prisoners remains a challenge but 
is an essential public health strategy to reduce the increasing HCV burden. 
Key Words: Hepatitis C; PWID; prisoner; treatment; prevention
1. Introduction
HCV infection is a leading cause of liver relat-
ed morbidity and mortality across Europe [130]. An 
estimated 14 million people are chronically infected 
with this blood borne virus in the European region 
[61, 130], with over 70,000 dying annually of HCV 
related liver cirrhosis and cancer [116]. Injecting drug 
use (IDU) is the major driver of the HCV epidemic 
in developed countries and now accounts for 80% of 
new infections in the European Union (EU) [37, 48]. 
Surveillance data on HCV infection is incomplete 
which impacts public health efforts to manage this 
important epidemic [29, 71, 72].  The incidence and 
prevalence of HCV infection is much higher in PWID 
and prisoners than the general population [27, 29, 
36, 48, 72, 97]. Since 2001 effective treatment with 
pegylated interferon and ribavirin has been available 
[59]. More recently the availability of simple and tol-
erable direct acting antivirals (DAA) have revolution-
ised the HCV treatment landscape, yet the majority 
of those infected remain undiagnosed and untreated 
[30, 53, 87, 123]. 
PWID and prisoners are some of the most mar-
ginalised people in society and despite having high 
rates of physical and psychiatric morbidity are un-
derserved by traditional health services [40, 41, 48]. 
PWID include those who have ever injected an illicit 
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drug. This population consists of both past injectors 
and present injectors [71]. A subgroup of PWID will 
also be receiving agonist opioid treatment (AOT), 
some of whom will continue to inject drugs [2, 71]. 
The differentiation between former and current injec-
tor is important since those that continue to inject are 
most at risk of HCV acquisition and transmission and 
are a key population to target for both treatment and 
prevention [37, 83]. 
In the literature, PWID and prisoners are often 
reported as two distinct groups but artificially so, as 
HCV infected prison populations typically represent 
a sub-group of the PWID population [27, 7].  PWID 
experience high rates of incarceration (56-90% ever 
being incarcerated), and previous incarceration is as-
sociated frequently with HCV infection and increased 
injecting risk in the community [37, 64, 112]. Recent 
prison release is also associated with heightened HCV 
transmission risk which is of particular concern since 
the majority of prisoners serve short prison sentences 
(> 12 months) [4, 98, 112, 132]. Managing the transi-
tion period between prison and community is seen as 
crucial to HCV public health strategies targeting pris-
oners and PWID [57, 112]. Successfully community 
linkage on release from prison enhances treatment 
outcomes and cost effectiveness [57, 85]. 
Understanding the HCV related disease burden 
and identifying barriers and enablers to treatment up-
take are essential to the planning and implementation 
of public health strategies aimed to HCV elimination 
[49, 53].  HCV prevention is essential to optimise 
the benefits of treatment and is also closely associ-
ated with re-infection rates and cost-effectiveness of 
treatment [73]. This review reports on HCV treatment 
and prevention in PWID and prisoners. It reports on 
the estimated disease burden, barriers and enablers, 
treatment guidelines, outcomes, re-infection rates and 
prevention (including the public health strategies of 
treatment as prevention and micro-elimination).  
2. Methods
A narrative review of the literature was under-
taken. The search engines Medline, PubMed, the 
Cochrane Library and Embase were searched for all 
articles published in the time frame 2008-2018 and 
in all languages.  Key search terms used were prison, 
prisoner*, inmate, combined with Hepatitis C and a 
range of other terms relevant to HCV treatment and 
prevention, including disease burden, barriers and 
enablers, outcomes and re-infection rates, cost-effec-
tiveness, treatment as prevention and prevention. The 
same search was repeating replacing prisoner with 
PWID.
Due to the recent advances in HCV manage-
ment, preference was given to systematic reviews and 
studies published in the last 5 years in high impact 
peer reviewed journals. The reference lists of the cho-
sen publications were also searched for additional ar-
ticles that might be relevant to the review. Websites 
from the following organisations; United Nations 
Office on Drugs and Crime (UNDOC), World Health 
Organisation (WHO), European Centre for Disease 
Prevention and Control (ECDC), European Monitor-
ing Centre for Drugs and Drug Addiction (EMCD-
DA) and Centre for Disease Control and Prevention 
(CDC) were searched for relevant reports. Reference 
lists from these reports were searched for additional 
articles relevant to this review. Grey and unpublished 
literature was not included. 
The term ‘prison’ is used in this review to en-
compass all places of detention associated with the 
criminal justice system, including prisons, remand 
centres (prisoners awaiting trial) and the American 
term jail (prisoners on remand and serving sentences 
of less than one year), juvenile detention facilities, 
pre-trial detention centres and extra-judicial detention 
centres for PWID. 
3. Results
3.1. HCV-related disease burden 
It is difficult to estimate the true extent of the 
global HCV related disease burden given the asymp-
tomatic nature of HCV infection and the poor access 
and engagement of those infected with medical ser-
vices [23, 85, 107, 108]. In some regions as many as 
75-90% of HCV positive individuals are unaware of 
their infection [128]. Globally 71 million people have 
chronic HCV infection with an estimated 5.6 million 
of these being PWID [49, 128]. Morbidity and mor-
tality continue to increase among PWID [97, 108]. 
Those chronically infected remain at risk for 
onward transmission and frequently progress to ad-
vanced fibrosis, cirrhosis, and hepatocellular carcino-
ma (HCC) [32, 108, 111].  An estimated 70-80% of 
individuals exposed to HCV develop chronic infec-
tion; if untreated, 3-11% will develop liver cirrhosis 
within 20 years, with associated risks of liver failure 
and HCC [43, 91]. The following factors have been 
identified to increase progression of liver disease: 
male gender, co-infection with HBV or HIV and al-
cohol consumption [79, 106]. 
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The prevalence of HCV related, end-stage liver 
disease and mortality are increasing [32, 111]. Ap-
proximately 27% of cirrhosis and 25% of HCC cases 
globally can be attributed to HCV [32]. HCV infected 
individuals have 2.4 times the risk of all-cause mor-
tality compared with the non-infected population 
(26.5 times the risk of liver-related mortality and 1.8 
times the risk of non-liver related mortality) [12, 32].
HCV related mortality surpassed mortality from 
HIV in the USA, primarily because of end-stage liver 
disease among members of the 1945-1965 birth co-
horts who have been living with HCV infection for 
20-30 years [80]. Modeling studies project that with-
out the scaling up of HCV treatment the associated 
disease burden will increase by 36% to 64% over the 
next decade [13]. 
Prioritising patients with advanced liver disease 
is the most effective strategy to reduce HCV related 
morbidity and mortality [13, 67].  In jurisdiction were 
access to DAA is limited by cost, active case finding 
of patients with liver disease is a priority [125, 128]. 
The immediate priority across Europe is to scale up 
HCV treatment in people with severe liver disease to 
reduce HCV related morbidity and mortality, as rap-
idly as possible [37].
3.2. HCV treatment 
 HCV treatment uptake among PWID and pris-
oners is low [2, 62, 83]. Until 2014, the standard 
treatment for HCV infection was pegylated interferon 
(PEG-IFN) and ribavirin (RBV). The length of treat-
ment was dependent on HCV genotype, 48 weeks 
for HCV genotypes 1, 4, 5, and 6 with expected sus-
tained virologic response (SVR) rates of 40-50% or 
24 weeks for HCV genotypes 2 and 3 and 80% SVR 
response rates [95]. 
Since 2014 the HCV treatment landscape has 
changed. The development of non-interferon based 
DAA therapies has meant a significant reduction in 
treatment duration (8-12 weeks), adverse side effects 
experienced and improved treatment outcomes (viral 
clearance >90%) [13, 39, 49, 100]. In contrast to pre-
vious treatments, the new drugs are effective in those 
with severe liver disease and against all genotypes 
and have fewer psychiatric side effects [100, 101]. 
The development of newer pan-genotype DAA has 
the potential to reduce treatment times even further 
and reduce the need for genotyping pre-treatment 
[100, 101]. This may have particular utility in pris-
on populations where short prison sentence length 
impacts in treatment uptake and completion [6, 53, 
87]. However, these treatments remain expensive and 
challenges remain to scaling up treatment in PWID 
and prisoners.  
3.3. Barriers and enablers 
Barriers to HCV treatment among PWID have 
been identified and include: concerns about side ef-
fects, limited knowledge of HCV, worries that treat-
ment will be rationed, experiences of treatment refus-
al due to drug use, competing priorities, experiencing 
stigma, criminalisation and difficulty accessing ser-
vices [49, 63, 114]. 
In the past, PWID generally had a negative view 
of interferon, and some physicians hesitated to pre-
scribe this drug because they feared that it may have 
unacceptable side effects, some resembling opioid 
withdrawal symptoms [31]. Parenteral application 
also presented a barrier to interferon use for many 
PWID [50]. At the practitioner level, perceptions 
about poor adherence, ongoing substance use, relapse 
to substance use, risk of exacerbating co-morbid psy-
chiatric disease and potential risk of re-infection have 
often been used as reasons for withholding therapy 
[109].
Interventions to enhance linkage to care include; 
facilitated referral for HCV assessment, scheduling of 
specialist appointments for clients, integrated HCV 
care, drug use and psychiatric services delivered by 
a multidisciplinary team with case management ser-
vices, with or without non-invasive liver disease as-
sessment [104]. 
Major barriers exist to the uptake of HCV treat-
ment in prisons. These include the high turnover and 
movement of incarcerated individuals, and poor link-
age to care [9, 131]. In some jurisdictions the high 
costs of DAA is a further barrier to widespread scale-
up of HCV treatment [56, 90].
Enablers to HCV treatment in prisons have been 
identified and these include; in-reach hepatology 
services, improved models of health care delivery, 
nurse-led clinics , telemedicine, increasing prison-
ers’ awareness and understanding of HCV infection 
and treatment options, educating both operational and 
clinical staff and involvement of peer educators in 
increasing knowledge and reducing stigma [17, 79]. 
Further enablers to HCV treatment uptake include 
prisoners relinquishing their parole eligibility to com-
mence treatment inside prison. As patients’ percep-
tions of Hepatitis C therapy are influenced by peers, 
such campaigns should consider involving peers in 
both planning and implementation [17].
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Prison potentially offers a relatively stable en-
vironment in which to commence treatment as they 
usually provide good access to health care providers 
and are organised around routine and structure [40, 
129]. Shorter, more tolerable treatment regimens 
with less monitoring requirements have the potential 
to overcome some of the identified barriers including 
the short length of the majority of prison sentences 
[101].
The availability of mobile elastography to assess 
the extent of HCV related liver disease along with 
movement of HCV treatment out of hospital-based 
services is further improving HCV treatment uptake 
and outcomes both in community settings and prisons 
[3, 117]. In the future this assessment may be further 
simplified by the use of amino transferase/platelet 
ratio index (APRI) or FIB-4 test [1, 34]. These tests 
have further utility in resource limited settings for the 
assessment of hepatic fibrosis rather than other nonin-
vasive tests that require more resources such as elas-
tography or Fibro Test [59].
3.4. Guidelines 
International guidelines recommend the prior-
itisation of HCV treatment for PWID and prisoners. 
Clinical guidelines at a European level recommend 
that current injecting by itself is not a contraindica-
tion to HCV treatment access [5, 74] and recommend 
that treatment be provided to PWID (current) who are 
at risk of transmitting infection to others, irrespective 
of disease stage [34].  The recommendation not to 
exclude PWID who are actively injecting drugs has 
the potential to remove some of the identified barri-
ers to HCV treatment. Globally, DAA availability is 
variable with many jurisdictions restricted access to 
contain cost. In resource limited settings access is of-
ten prioritised based on the severity of liver disease. 
This approach improves morbidity and mortality but 
does not impact on treatment as a prevention strategy. 
Treatment decisions need to be individualised taking 
into consideration social circumstances and the avail-
ability of support, as well as the anticipated clinical 
benefit of achieving an SVR.
3.5. Treatment outcomes 
Treatment outcomes are measured by SVR 
rates; defined as the proportion of patients with unde-
tectable HCV RNA measured at 12 or 24 weeks post 
treatment. In almost all cases patients achieving SVR 
remain virus free and are considered cured [34].  It is 
not clear how many PWID have been treated for HCV 
infection but the evidence suggests that rates are low 
[74]. There is increasing evidence that treatment for 
PWID is highly effective; two systematic reviews 
suggest that SVR among PWID are comparable to 
those reported by large randomised controlled trials 
of pegIFN/RBV treatment [5, 59].
SVR and adherence to treatment of HCV can 
result in acceptable outcomes in individuals who re-
port current injecting drug use and who meet standard 
eligibility criteria for commencing HCV treatment 
[19]. Owing to the small number of studies available, 
it was not possible to investigate other factors, such 
as the mode of treatment delivery and the availabil-
ity of treatment support, that are likely to impact on 
treatment outcomes.  Models of community-based 
HCV treatment have been established and evaluated 
for efficacy in various jurisdictions [9. 104]. A recent 
systematic review concluded that the available data 
(while limited) supports the efficacy of community-
based HCV treatment and the potential for this ap-
proach to increase treatment uptake [104]. Among 
PWID on AOT drug use at baseline and during treat-
ment does not affect adherence or treatment outcomes 
and active drug use should not exclude PWID from 
access to DAA [30].
Prison-based HCV treatment achieves similar 
or better outcomes to community-based treatment, 
with those not released or transferred during treat-
ment doing particularly well [6]. Inter-prison transfer 
and release have a negative impact on completion and 
should be avoided where possible [6, 87, 112]. Link-
age to community-based treatment on release im-
proves outcomes and cost-effectiveness and reduces 
the risk associated with the post-release period [65, 
112]. Many of the prison-based treatment outcomes 
studies are from the interferon area of treatment 
where many prisoners were excluded from treatment 
due do stricter eligibility criteria and fears regard-
ing adverse side effects. More recent studies using 
DAA have also shown very promising outcomes and 
a number of prisons have reported micro-elimination 
of HCV from their prison setting [11, 100, 102].
3.6. Re-infection rates
The risk of HCV re-infection among PWID fol-
lowing achieving an SVR is considered relatively low 
(1–5% per year), but there is considerable uncertainty 
around this estimate among those who continue to 
inject after achieving an SVR [6, 19, 33].  Addition-
ally, reported rates of re-infection among PWID are 
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ment between community and prison is maintained 
on release [37]. The economics of prison-based HCV 
treatment is complicated by the fact that most of the 
benefits accrued from treatment occur in the com-
munity after the prisoner is released. In jurisdictions 
where the cost of HCV treatment is carried by the 
prison health care budget there may be reluctance on 
prison authorities to actively screening and treat HCV 
infected prisoners. This is of particular importance in 
US prisons where a number of court cases have sup-
ported the rights of HCV infected prisoners to access 
treatment and where prison budgets are directly re-
sponsible for its cost. Increasingly public health spe-
cialists recommend that prison health care systems 
should fall under the remit of national public health 
care structures and that good prison health is good 
public health [40, 129]. 
Changing funding models in some countries 
have made DAA treatment more cost-effective. Many 
national governments have negotiated packages based 
on a maximum drug spend per year which encourages 
health care systems to actively find and treat those 
infected. In Australia this model has been shown to be 
particularly effective [8, 54]. The UK government has 
developed a model where drug companies provide 
financial support initiatives to increase screen and 
HCV treatment in hard to reach groups while agree-
ing to pay an agreed annual sum for unlimited access 
to DAA therapies [99]. 
3.8. ‘Treatment as prevention’
Treating HCV infected prisoners and PWID has 
the potential to cure the individual but also to reduce 
transmission and disease burden at a population level 
[47, 60]. The impact on treatment as a prevention 
strategy is dependent both on the effectiveness and 
levels of treatment [60, 85, 86, 126]. By inducing a 
reduction in infectiousness in PWID and prisoners, 
treatment leads to a reduction in HCV transmission 
and an eventual decrease in advanced disease and, 
importantly, potential control of the HCV epidemic. 
Results from a number of mathematical modelling 
papers have raised the expectation that a moderate 
level of HCV treatment in PWID could lead to a sig-
nificant reduction in the prevalence and incidence of 
HCV infection [18, 47, 60, 86].
It is hypothesised that an HCV treatment strate-
gy would be especially effective if provided in combi-
nation with other primary interventions, such as AOT 
and NSP, by reducing the risk of spread by removing 
individuals who have been successfully treated from 
very likely subject to considerable selection bias for 
interferon-based treatments [33]. A number of studies 
have reported higher re-infection rates among current 
PWID and identified older age and injecting drug use 
at the end of or post-treatment [89]. 
However, the rate of HCV re-infection after 
successful treatment in inmates is high, particularly 
among those who continue to inject drugs [78, 81]. 
Studies have reported an overall re-infection rate of 
5.27 cases per 100 person-years. Re-infection in-
cidence was significantly higher among active drug 
users, HIV co-infected and those engaging in more 
than one risk behaviour after treatment [78, 81]. Pre-
ventative interventions at diagnosis and during and 
after HCV treatment should be strongly reinforced. 
With less restrictive treatment guidelines and expand-
ing DAA treatment eligibility to increasing numbers 
of PWID, increasing levels of re-infection are to be 
expected [54].  Individual- and population-level ef-
forts to address and prevent re-infection should there-
fore be undertaken when providing HCV care for 
people with on-going risk behaviour. Constructive 
strategies include acknowledgement, education and 
counselling, harm reduction optimisation, scaled-up 
treatment including treatment of injecting networks, 
post-treatment screening, and rapid retreatment of re-
infections [92]. 
Re-infection is a major concern and impacts on 
both the cost effectiveness and prevention benefits of 
treatment. There is a need for post-treatment surveil-
lance and wide spread implementation of strategies 
to enhance HCV prevention, such as access to high-
coverage needle and syringe programmes (NSP) and 
AOT to minimise HCV re-infection risk [89].
3.7. Cost-effectiveness
The cost of DAAs, while decreasing, is signifi-
cant and recognised as a barrier to treatment expan-
sion. Modeling studies show that DAA are cost-ef-
fective due to the health care savings associated with 
reduced HCV related morbidity [25, 46]. Studies 
have shown that treatment of PWID with interferon-
based treatment is cost-effective compared with no 
treatment [88, 120]. Further modeling studies in the 
UK have shown that treatment with DAA was cost-
effective in models projections of increased uptake 
of treatment [37, 46, 119] but levels of re-infection 
could limit the effectiveness of these models.  
Similarly, treatment of prisoners with short act-
ing DAA regimes is cost-effective, in particular where 
treatment uptake is increased and continuity of treat-
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populations. Micro-elimination is less daunting, less 
complex, and less costly than full-scale, country-level 
initiatives to eliminate HCV, and it can build momen-
tum by producing small victories that inspire more 
ambitious efforts [75]. The micro-elimination ap-
proach encourages stakeholders who are most knowl-
edgeable about specific populations to engage with 
each other and also promotes the uptake of new mod-
els of care. PWID and prisoners are two key popula-
tions that could benefit from this approach.  A recent 
study reported on micro-elimination of HCV infec-
tion through rapid uptake of government-funded DAA 
therapy in an Australian prison. During a 22-month 
period, 119 patients-initiated HCV treatment which 
reduced the rate of chronic HCV infection from 12% 
to 1% [11].
3.10. Prevention
The rates of new HCV infections annually are 
significant (1.7 million in 2015) with a quarter of 
these attributable to current IDU [128]. HCV ex-
posure is related to the levels of infection in at-risk 
populations and availability and use of harm reduc-
tion [73, 75, 126]. PWID are at particular high-risk 
of infection during the initial years of injecting [52, 
105].  Evidence shows that traditional harm reduc-
tion measures such as AOT and NSP are effective in 
reducing self-reported syringe sharing [7]. Both in-
terventions can reduce transmission of HIV and HCV 
particularly when provided together [7, 47, 49, 73, 
96]. Recently, there has been a further strengthening 
of the evidence base from non-European countries, 
with results from the Vancouver Injecting Drug Use 
Study in Canada and two other prospective studies of 
PWID, one in Australia and one in San Francisco in 
the United States all of which reported that AOT can 
reduce the risk of HCV acquisition by 50-80% [94, 
118, 121].
This approach is supported by the newly agreed 
EU minimum quality standards for prevention [37]. 
Screening for HCV and educating those who test 
positive about how to avoid infecting others, treating 
those who test positive to remove them from the pool 
of transmitters and changing policies and behaviours 
to prevent both new infections in the uninfected and 
re-infection among those successfully treated [37].
 NSP and AOT have been increasingly estab-
lished, with 90 countries having NSP to some degree 
and 80 at least one AOT programme operational by 
2016 [122]. However, coverage remains poor and 
data on the quality of many of these services is un-
‘the pool of infected’ [47, 51]. The reality is more 
complex, and real-world evidence of the impact of 
scaling up HCV treatment is lacking. PWID are a 
mixed population of individuals at risk of acquiring 
and transmitting infection, including current injec-
tors, those who are in treatment or prison or have re-
cently ceased injecting and are at high risk of relapse. 
Furthermore, patterns of drug use along with risk be-
haviour change over time e.g. emerging psychoactive 
drugs, HIV outbreaks [44]. Existing estimates of in-
jecting drug use prevalence rarely captures the whole 
[71]. These factors could change over time (in terms 
of scaling up or even disinvestment) and impact on 
the intervention and will need to be measured and in-
corporated into the analysis. 
The public health strategy of treatment as pre-
vention has been driven by the introduction of DAA 
[51, 60, 77, 87]. There is now a possibility of achiev-
ing better treatment retention and outcomes for 
PWID and prisoners.  Research shows that invest-
ment in HCV treatment, even for those who continue 
to inject drugs, is justified on public health grounds 
[47, 51]. The newer HCV treatment regimens are less 
complex to administer and, therefore, more appropri-
ate to use in primary care, prison and drug treatment 
settings [127]. While prisons would seem ideal loca-
tions to implement treatment as prevention strategies, 
concerns have been expressed about associated ethi-
cal issues. The unequal relationship between prisoner 
and health provider may impact on consent issues and 
those prisoners who have been successfully treated 
may not have access to appropriate harm reduction 
measures to protect against re-infection [77]. Fur-
thermore, the short duration of sentences for PWID 
(predominately incarcerated for drug related crimes) 
may negatively impact HCV treatment as prevention 
among prisoners [86, 87].
Peer-involved and peer-led services can help to 
engage those who are reluctant to draw on tradition-
al services [3, 110, 113, 124]. Concerns have been 
expressed that an increased impetus on Hepatitis C 
‘treatment as prevention’ might threaten harm reduc-
tion ‘prevention as prevention’ initiatives such as 
AOT and NSP [16]. 
3.9. Micro-elimination
Increasingly in the HCV literature the strategy 
of micro-elimination is reported on [24, 75, 102]. 
Micro-elimination entails pursuing elimination goals 
in discrete populations through multi-stakeholder ini-
tiatives that tailor interventions to the needs of these 
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nity-based programmes exists, prison AOT facilitates 
continuity of treatment and longer-term benefits can 
be achieved [58]. For prisoners in AOT before impris-
onment, prison AOT provides treatment continuity. 
Disruption of AOT continuity, especially due to brief 
periods of imprisonment, is associated with very sig-
nificant increases in HCV incidence [112].
In Spanish prisons, PWID experience a fivefold 
lower incidence of HCV if on AOT [82]. Similarly, af-
ter introducing prison AOT in Scotland, current cov-
erage of 57% among PWID, evidence suggests HCV 
incidence among incarcerated PWID reduced, and is 
now lower than among community PWID [115].  A 
recent cross-sectional survey of harm reduction cov-
erage in European prisoners found that, twenty-one 
countries (84%) provide HCV treatment in prison 
[14]. However, the extent of coverage of these treat-
ment programs varies widely. Two countries (8%) 
have NSP officially available in prisons in all parts of 
the country. Eleven countries (44%) provide AOT in 
prisons in all parts of the country without additional 
requirements [14]. 
4. Discussion
Despite PWID and prisoners carrying a dispro-
portionate amount of the HCV disease burden, rates 
of HCV screening and treatment remain low [27, 72, 
87, 97, 108, 128]. Public health strategies aimed at 
HCV elimination recommend the targeting of these 
two groups as a priority [49]. This review found that 
HCV related liver mortality and morbidity is increas-
ing globally and if it remains unchecked will cause 
700,000 deaths annually by 2030 [97, 108]. 
Recent developments in HCV management have 
increased optimism among health care providers and 
those infected with HCV and it is now recognised that 
we have the tools to cure, eliminate and prevent HCV 
[11, 21, 49]. The treatment of PWID and prisoners 
is challenging. Central to this challenge is the mar-
ginalisation and the associated stigma experienced by 
these two groups [66, 103, 114, 131]. Despite hav-
ing much higher levels of physical and psychiatric 
morbidity, PWID and prisoners do not utilise medi-
cal services [40]. Prison can offer the opportunity for 
this group to engage with services, but benefits can be 
eroded by the complexity of prison health care deliv-
ery, the continuing stigma that prisoners experience 
while incarcerated and failures in community linkage 
on release [40, 85, 112, 129, 131].
Despite recent reductions in cost, treatment with 
DAA remains expensive. Based on modeling stud-
known [37, 73]. These initiatives are fragile, politi-
cally unpopular, under-resourced and increasingly 
undermined by a ‘recovery agenda’ that prioritises 
abstinence.  In many countries in Europe, particularly 
in Eastern Europe and Eurasia, interventions such as 
AOT can be limited or prohibited [37, 38, 73].
 In 2017, of 179 countries with evidence of 
IDU, some level of NSP services was available in 93 
countries, and 86 countries had evidence of AOT im-
plementation [73]. 57 countries had data available to 
estimate NSP coverage, and 60 countries to estimate 
AOT coverage [73]. Coverage varied widely between 
countries but was most often low when compared to 
WHO indicators (<100 needle-syringes distributed 
per PWID per year; <20 AOT recipients per PWID 
per year). There are an estimated 33 needle-syringes 
distributed via NSP per PWID annually, and 16 AOT 
recipients per 100 PWID globally. Less than 1% of 
PWID live in countries with high coverage of both 
NSP and AOT (>200 needle-syringes distributed per 
PWID and >40 AOT recipients per 100 PWID) [122].
The HCV incidence among general prisoners is 
estimated to be 1·4 per 100 person-years (py; 95% 
CI: 0·1, 2·7; k=4), and 16·4 per 100py (95% CI: 0·8, 
32·1; k=3) among prisoners with a history of IDU 
with larger regional and country variations [72]. Al-
though access to HCV screening for PWID seems to 
be poorer in prison than in the community, access to 
harm reduction measures is even more limited [14, 
73]. Approximately 60 out of more than 10,000 pris-
ons worldwide provide needle exchange. HCV pre-
vention is almost exclusively limited to verbal advice, 
leaflets and other measures directed to cognitive be-
havioural change [14]. While the extent of multiple 
risk behaviours for HCV in prisons is challenging, the 
setting does offer an ideal opportunity to provide a 
range of evidence-based interventions that can reduce 
HCV infection [14, 69, 72]. These include AOT, NSP 
and condom availability. These have the added advan-
tage of reducing HIV transmission and, in the case 
of AOT, fatal overdose in the immediate post-release 
period [15, 20, 96]. Despite the evidence base for the 
effectiveness of these interventions in the reduction of 
the transmission of blood borne viruses (BBVs), there 
is poor coverage of these in prisons globally [14, 38, 
129].
Benefits of prison AOT are similar to those in 
community settings [58]. AOT presents an opportu-
nity to recruit problem opioid users into treatment, to 
reduce illicit opioid use, injecting and risk behaviours 
in prison and potentially minimise overdose risks on 
release [22, 26, 45, 58, 70]. If liaison with commu-
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pan-genotypic regimes are required to optimise this 
opportunity [35, 69, 93, 101]. In the long term, drug 
policy changes are required to reduce the criminali-
sation of drug users and the levels of communicable 
diseases globally [10, 42]. 
Scaling up of treatment will require the devel-
opment of effective working partnerships between 
specialist services working with PWID and prison-
ers and those offering HCV care [9, 79, 104]. In the 
past, referral pathways for PWID and prisoners into 
specialist hepatitis care have represented a critical 
weak link [63, 114, 131]. This is now changing, and 
novel approaches have been developed where HCV 
treatment is provided alongside community AOT and 
directly in prison settings [11, 104]. There remains 
a need for these to be expanded and supported so 
that they become the first line of HCV care for the 
majority of PWID.  While DAA promise more effi-
cacious treatment with limited side effects, social is-
sues including criminalisation, stigma, homelessness 
and inflexible service provision are likely to continue 
to impede treatment uptake [49, 55, 68, 103, 131]. 
Clinical guidance promoting relaxed eligibility crite-
ria holds the potential to break down current barriers 
to HCV treatment access and uptake for PWID and 
prisoners [34]. Treatment and prevention of HCV in-
fection in PWID and prisoners must be specifically 
adapted to these marginalised groups. DAA have the 
potential to remove many of the identified barriers to 
treatment but without innovative approaches to treat-
ment delivery treatment uptake and effectiveness will 
be compromised. 
Close collaboration between all profession-
als involved in HCV care should underpin models 
of treatment delivery. Evidence based harm reduc-
tion measures such as AOT and NSP will need to be 
scaled up both in the community and prison in order 
to reduce new HCV infection, minimise the risk of re-
infection and necessary if ‘HCV elimination’ is ever 
to become a reality. HCV treatment and prevention 
strategies that view prisons as a key location to target 
the most marginalised HCV infected PWID are likely 
to have the greatest impact on the management of 
this treatable and preventable global epidemic. These 
strategies will need to be informed and evaluated by 
appropriate, comprehensive and reliable surveillance 
data which is presently incomplete and lacking in 
many jurisdictions. 
ies this review found that HCV treatment in PWID 
and prisoners is cost-effective but ultimately this is 
dependent on real life rates of re-infection [85]. Many 
high-risk patients for transmission were excluded 
from interferon-based treatment and with the scal-
ing up of HCV treatment and the use of treatment as 
prevention these patients will have to be treated but 
more importantly will have to be protected from re-
infection by high coverage of both AOT and NSP [47, 
49, 53]. In resource limited jurisdictions the selection 
of who to treat is challenging. Treating those with ad-
vanced HCV-related liver disease will reduce morbid-
ity and mortality but will have little impact on HCV 
transmission levels [28, 47, 76]. Insufficient treatment 
levels among PWID, particularly those who continue 
to inject, will reduce the effectiveness of “treatment 
as prevention”, increase rates of re-infection and limit 
the cost-effectiveness of treatment [53, 86].  Planning 
long-term strategies to optimise the benefits of HCV 
treatment among PWID and prisoners requires that 
accurate and up to date surveillance data is available 
to inform the implementation and evaluation of these 
programs [28, 76].
Despite growing evidence for the benefits of 
AOT and NSP in reducing HCV transmission, rates 
of coverage is inconsistent and low across Europe 
[14, 70, 73, 122]. Present levels are likely to be in-
sufficient to effectively prevent HIV and HCV trans-
mission. This is even more problematic in prison 
settings [4]. A number of studies reported the protec-
tive nature that incarceration provided against HCV 
acquisition. This protection occurred in jurisdiction 
with high levels of prison AOT [82, 115].  Scaling 
up of interventions for PWID and prisoners remains 
a crucial priority for halting both the HIV and HCV 
epidemics [73].
The short prison sentence served by the major-
ity of prisoners has been identified as a major block 
to HCV treatment uptake in this group [84, 87, 112]. 
The advent of new shorter acting pan-genotypic DAA 
has the potential to increase the numbers access-
ing and completing treatment while in prison [100, 
101].  Community linkage, facilitating the comple-
tion of treatment on release, could have a similar 
impact [87, 112]. Ongoing criminalisation of PWID 
across Europe ensures high levels of HCV infections 
in European prisons [4, 72]. On short-term bases this 
could be viewed as an opportunity to engage this 
underserved at risk group with HCV care [87, 98]. 
Targeted and ambitious screening and treatment strat-
egies including opt-out screening, reflex-RNA test-
ing, in-reach fibroscanning and use of short acting 
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of the Infectious Diseases Society of America. 67(3): 
460-463.
12. Baumert T. F., Juhling F., Ono A., Hoshida Y. (2017): 
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Hepatitis C disease transmission and treatment uptake: 
impact on the cost-effectiveness of new direct-acting 
antiviral therapies. The European journal of health 
economics : HEPAC : health economics in prevention 
and care. 18(8): 1001-1011.
14. Bielen R., Stumo S. R., Halford R., Werling K., Reic 
T., Stover H., Robaeys G., Lazarus J. V. (2018): Harm 
reduction and viral hepatitis C in European prisons: a 
5. Conclusions
The growing global HCV disease burden carried 
by PWID and prisoners in developed countries is a 
major public health concern and one which requires 
innovative and targeted approaches to combat. De-
spite having the tools to both cure and prevent this 
epidemic, major challenges remain to identify and 
treat those infected. The silent nature of HCV infec-
tion coupled with the marginalisation of those most 
at risk impedes efforts to eliminate HCV as a major 
public health concern. HCV infected prisoners are a 
subgroup of HCV infected PWID and prisons remain 
key locations to target this group for HCV screening, 
treatment and prevention. Linking community and 
prison services and supporting transition between 
these locations has the potential to increase the effec-
tiveness of any public health HCV strategy.  The cost 
of DAA therapies is a major block to expansion of 
HCV treatment and will need to be addressed if HCV 
elimination is to become a reality. Medical and politi-
cal leadership is required to tackle the links between 
social deprivation, drug use and its criminalisation, 
marginalisation and stigma. As we strive to overcome 
the many barriers associated with HCV treatment and 
prevention, evidence of micro-elimination of HCV in 
prisons, community drug treatment locations and in-
jecting networks can continue to motivate health care 
professionals involved in HCV and provide optimism 
to those infected.  
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